Literature DB >> 7581302

Autoantibodies, neurotoxins and the nervous system.

A Vincent1, M Roberts, H Willison, B Lang, J Newsom-Davis.   

Abstract

Myasthenia gravis, the Lambert-Eaton myasthenic syndrome, and acquired neuromyotonia are three disorders of the neuromuscular junction or motor nerve that are caused by autoantibodies to ion channel proteins: acetylcholine receptors, voltage-gated calcium channels and voltage-gated potassium channels, respectively. The antibody titres can be measured using the relevant 125I-neurotoxins to label the extracted channels. Other disorders of the peripheral motor nerve are associated with antibodies to gangliosides. Sera with raised levels of anti-ganglioside antibodies have direct effects on the function of the distal motor nerve and motor nerve terminal. These conditions can be improved by therapies designed to reduce circulating antibodies. Antibodies that bind to neuronal surface antigens are proving to be of great clinical importance and interest in neurological disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7581302     DOI: 10.1016/0928-4257(96)80110-0

Source DB:  PubMed          Journal:  J Physiol Paris        ISSN: 0928-4257


  3 in total

1.  Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema.

Authors:  Nicola Marchi; Giulia Betto; Vincent Fazio; Quinyuan Fan; Chaitali Ghosh; Andre Machado; Damir Janigro
Journal:  Epilepsia       Date:  2009-01-21       Impact factor: 5.864

Review 2.  Maternal and fetal antibrain antibodies in development and disease.

Authors:  Elizabeth Fox; David Amaral; Judy Van de Water
Journal:  Dev Neurobiol       Date:  2012-09-04       Impact factor: 3.964

Review 3.  Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis.

Authors:  Gerda Ricken; Carmen Schwaiger; Desiree De Simoni; Valerie Pichler; Julia Lang; Sarah Glatter; Stefan Macher; Paulus S Rommer; Petra Scholze; Helmut Kubista; Inga Koneczny; Romana Höftberger
Journal:  Front Neurol       Date:  2018-10-10       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.